Jason Butler
Stock Analyst at JMP Securities
(4.52)
# 267
Out of 4,967 analysts
139
Total ratings
48.59%
Success rate
31.84%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $33 → $95 | $81.03 | +17.24% | 4 | Jul 23, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $17.63 | +58.82% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $25.99 | +42.36% | 14 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $13.50 | +188.89% | 5 | Jun 24, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $6 | $4.51 | +33.04% | 11 | Jun 12, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $78 → $29 | $8.20 | +253.66% | 10 | May 27, 2025 | |
| TTD The Trade Desk | Maintains: Market Outperform | $115 → $100 | $54.66 | +82.95% | 1 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Market Outperform | $42 → $38 | $18.38 | +106.75% | 8 | May 7, 2025 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $35.33 | +120.78% | 16 | Apr 10, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Market Outperform | $17 → $18 | $9.07 | +98.46% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $2.22 | +80.18% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $712.24 | -1.58% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $10.12 | +226.09% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $7.12 | +26.40% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $72 → $73 | $73.15 | -0.21% | 13 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $3.77 | +138.73% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.39 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $14.83 | +28.12% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $1.32 | +1,566.67% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.41 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $7.38 | +569,368.36% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $8.40 | +1,280.95% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $3.71 | +142.59% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.28 | - | 1 | Dec 2, 2020 |
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Market Outperform
Price Target: $33 → $95
Current: $81.03
Upside: +17.24%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $17.63
Upside: +58.82%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $25.99
Upside: +42.36%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $13.50
Upside: +188.89%
Precigen
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $4.51
Upside: +33.04%
Prothena Corporation
May 27, 2025
Maintains: Market Outperform
Price Target: $78 → $29
Current: $8.20
Upside: +253.66%
The Trade Desk
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $54.66
Upside: +82.95%
Viridian Therapeutics
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $18.38
Upside: +106.75%
Cytokinetics
Apr 10, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $35.33
Upside: +120.78%
Zevra Therapeutics
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $9.07
Upside: +98.46%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $2.22
Upside: +80.18%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $712.24
Upside: -1.58%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $10.12
Upside: +226.09%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $7.12
Upside: +26.40%
Nov 1, 2024
Maintains: Market Outperform
Price Target: $72 → $73
Current: $73.15
Upside: -0.21%
Oct 8, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $3.77
Upside: +138.73%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.39
Upside: -
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $14.83
Upside: +28.12%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $1.32
Upside: +1,566.67%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.41
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $7.38
Upside: +569,368.36%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $8.40
Upside: +1,280.95%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $3.71
Upside: +142.59%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.28
Upside: -